2. Search Result
Search Result
Results for "

ain

" in MedChemExpress (MCE) Product Catalog:

47

Inhibitors & Agonists

1

Biochemical Assay Reagents

1

Inhibitory Antibodies

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-P9927
    Secukinumab

    ain457

    		 Interleukin Related Inflammation/Immunology Cancer
    Secukinumab (AIN457) is a high affinity, human monoclonal antibody targeted against interleukin (IL)-17A. Secukinumab is the first-in-class anti-IL-17 agent used for the research of plaque psoriasis, ankylosing spondylitis and psoriatic arthritis .
    Secukinumab
  • HY-145803
    KIF18A-IN-3

    		Microtubule/Tubulin Cancer
    KIF18A-IN-3 is a potent KIF18A inhibitor (IC50=61 nM). KIF18A-IN-3 causes significant mitotic arrest and increases the number of mitotic cells in tumor tissues. KIF18A-IN-3 can be used for researching cancer .
    KIF18A-IN-3
  • HY-145802
    KIF18A-IN-2

    		Microtubule/Tubulin Cancer
    KIF18A-IN-2 is a potent KIF18A inhibitor (IC50=28 nM). KIF18A-IN-2 causes significant mitotic arrest and increases the number of mitotic cells in tumor tissues. KIF18A-IN-2 can be used for researching cancer .
    KIF18A-IN-2
  • HY-146221
    Dyrk1A-IN-5

    		DYRK Neurological Disease
    Dyrk1A-IN-5 (compound 5j) is a potent and selective DYRK1A inhibitor, with an IC50 of 6 nM. Dyrk1A-IN-5 dose-dependently reduces the phosphorylation of Thr434 in SF3B1, with an IC50 of 0.5 μM. Dyrk1A-IN-5 inhibits phosphorylation of tau at Thr212, with an IC50 of 2.1 μM. Dyrk1A-IN-5 can be used for Down syndrome research .
    Dyrk1A-IN-5
  • HY-158237
    PDE10A-IN-3

    		Phosphodiesterase (PDE) Neurological Disease
    PDE10A-IN-3 (Compound 8a) is an inhibitor of phosphodiesterase 10A (PDE10A). PDE10A-IN-3 can be used in schizophrenia research .
    PDE10A-IN-3
  • HY-149915
    MAT2A-IN-10

    		Methionine Adenosyltransferase (MAT) Cancer
    MAT2A-IN-10 (Compound 28) is an orally active MAT2A inhibitor with an IC50 of 26 nM. MAT2A-IN-10 can be used for the research of cancer .
    MAT2A-IN-10
  • HY-131973
    PDE10A-IN-2 hydrochloride

    		Phosphodiesterase (PDE) Cardiovascular Disease Metabolic Disease
    PDE10A-IN-2 hydrochloride is a potent, highly selective and orally active phosphodiesterase 10A (PDE10A) inhibitor with an IC50 of 2.8 nM. PDE10A-IN-2 hydrochloride shows selectivity of >3500-fold against other PDE subtypes. PDE10A-IN-2 hydrochloride can be used for pulmonary arterial hypertension (PAH) research .
    PDE10A-IN-2 hydrochloride
  • HY-162010
    MAT2A-IN-13

    		Methionine Adenosyltransferase (MAT) Cancer
    MAT2A-IN-13 is a potent and orally active methionine adenosyltransferase 2A (MAT2A) inhibitor with a favorable pharmacokinetic profile. MAT2A-IN-13 shows in vivo potency in an HCT-116 MTAP-deleted xenograft model. MAT2A-IN-13 can be used for MTAP-Deleted tumors treatment research .
    MAT2A-IN-13
  • HY-157478
    CSNK2A-IN-1

    		Casein Kinase Infection
    CSNK2A-IN-1 (compound 7C) is a selective CSNK2A inhibitor. CSNK2A-IN-1 has antiviral activity and improved selectivity over PIM3 .
    CSNK2A-IN-1
  • HY-163182
    CSNK2A-IN-2

    		Casein Kinase Infection
    CSNK2A-IN-2 (compound 6c) is a selective CSNK2A inhibitor with antiviral activity. CSNK2A-IN-2 exhibits an inhibitory effect on viral replication and is selective for PIM3 .
    CSNK2A-IN-2
  • HY-145827
    KIF18A-IN-4

    		Microtubule/Tubulin Cancer
    KIF18A-IN-4 is a moderately potent ATP and microtubule (MT) noncompetitive KIF18A inhibitor (IC50=6.16 μM). KIF18A-IN-4 has selectivity against a large panel of mitotic kinesins and kinases, and does not show any direct effects on tubulin assembly. KIF18A-IN-4 exhibits anti-tumor activity .
    KIF18A-IN-4
  • HY-145034
    KIF18A-IN-1

    		Microtubule/Tubulin Inflammation/Immunology Cancer
    KIF18A-IN-1 is a mitotic kinesin KIF18A inhibitor extracted from patent WO2021026098A1 example 100-13. KIF18A-IN-1 exhibits anti-tumor activity .
    KIF18A-IN-1
  • HY-144179
    MAT2A-IN-4

    		Methionine Adenosyltransferase (MAT) Cancer
    MAT2A-IN-4 is a methionine adenosyltransferase 2A (MAT2A) inhibitor extracted from patent WO2020123395A1 compound 426 . MAT2A-IN-4 can be used for the research of cancer .
    MAT2A-IN-4
  • HY-162107
    Dyrk1A-IN-6

    		DYRK Neurological Disease
    Dyrk1A-IN-6 (compound 7cc) is an EGCG-like non-competitive inhibitor of DYRK1A. Dyrk1A-IN-6 can be used to alleviate cognitive defects in Down syndrome models .
    Dyrk1A-IN-6
  • HY-158165
    DNMT3A-IN-3

    		DNA Methyltransferase Cancer
    DNMT3A-IN-3 is an allosteric DNA methyltransferase 3A (DNMT3A) inhibitor. DNMT3A-IN-3 binds and disrupt protein-protein interactions (PPIs) at the DNMT3A tetramer interface .
    DNMT3A-IN-3
  • HY-115982
    NS5A-IN-3

    		HCV Protease Infection
    NS5A-IN-3 (Compound 15) is a potent inhibitor of NS5A. NS5A-IN-3 has extremely high potency against HCV genotype 1b, improved activity against genotype 3a (GT 3a) and good metabolic stability. NS5A-IN-3 exhibits a higher resistance barrier than daclatasvir against genotype 1b . NS5A-IN-3 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    NS5A-IN-3
  • HY-147066
    Dyrk1A-IN-4

    		DYRK Cancer
    Dyrk1A-IN-4 (compound 48) is a potent and orally active DYRK1A and DYRK2 inhibitor with IC50s of 2 nM and 6 nM, respectively. Dyrk1A-IN-4 has anticancer effects .
    Dyrk1A-IN-4
  • HY-147760
    Dyrk1A-IN-2

    		DYRK Metabolic Disease
    Dyrk1A-IN-2 (Compound 63) is a DYRK1A inhibitor with an EC50 of 37 nM. Dyrk1A-IN-2 exhibits highly potent human β-cell replication-promoting activity and low cytotoxicity .
    Dyrk1A-IN-2
  • HY-141890
    BAZ1A-IN-1

    		Epigenetic Reader Domain Cancer
    BAZ1A-IN-1 is a potent inhibitor of BAZ1A (bromodomain-containing protein). BAZ1A-IN-1 shows a KD value of 0.52 μM against BAZ1A bromodomain. BAZ1A-IN-1 shows good anti-viability activity against cancer cell lines expressing a high level of BAZ1A, but weak or no activity against cancer cells with a low expression level of BAZ1A .
    BAZ1A-IN-1
  • HY-144181
    MAT2A-IN-5

    		Methionine Adenosyltransferase (MAT) Cancer
    MAT2A-IN-5 is a potent inhibitor of MAT2A. The expression level of MAT2A is abnormally elevated in several types of tumors, including gastric, colon, liver and pancreatic cancers. MAT2A-IN-5 reduces the proliferative activity of MTAP-deficient cancer cells. MAT2A-IN-5 has the potential for the potential for the research of cancer diseases (extracted from patent WO2021254529A1, compound 1) .
    MAT2A-IN-5
  • HY-144184
    MAT2A-IN-6

    		Methionine Adenosyltransferase (MAT) Cancer
    MAT2A-IN-6 is a potent inhibitor of MAT2A. The expression level of MAT2A is abnormally elevated in several types of tumors, including gastric, colon, liver and pancreatic cancers. MAT2A-IN-6 reduces the proliferative activity of MTAP-deficient cancer cells. MAT2A-IN-6 has the potential for the potential for the research of cancer diseases (extracted from patent WO2021254529A1, compound 18) .
    MAT2A-IN-6
  • HY-144185
    MAT2A-IN-7

    		Methionine Adenosyltransferase (MAT) Cancer
    MAT2A-IN-7 is a potent inhibitor of MAT2A. The expression level of MAT2A is abnormally elevated in several types of tumors, including gastric, colon, liver and pancreatic cancers. MAT2A-IN-7 reduces the proliferative activity of MTAP-deficient cancer cells. MAT2A-IN-7 has the potential for the potential for the research of cancer diseases (extracted from patent WO2021254529A1, compound 24) .
    MAT2A-IN-7
  • HY-142930
    MAT2A-IN-3

    		Somatostatin Receptor Cancer
    MAT2A-IN-3 is a potent inhibitor of MAT2A. The expression level of MAT2A is abnormally high in several types of tumors, including gastric, colon, liver and pancreatic cancers. MAT2A-IN-3 reduces the proliferative activity of MTAP-deficient cancer cells. MAT2A-IN-3 has the potential for the research of cancer diseases (extracted from patent WO2019191470A1, compound 265) .
    MAT2A-IN-3
  • HY-142929
    MAT2A-IN-2

    		Somatostatin Receptor Cancer
    MAT2A-IN-2 is a potent inhibitor of MAT2A. The expression level of MAT2A is abnormally high in several types of tumors, including gastric, colon, liver and pancreatic cancers. MAT2A-IN-2 reduces the proliferative activity of MTAP-deficient cancer cells. MAT2A-IN-2 has the potential for the research of cancer diseases (extracted from patent WO2020243376A1, compound 172) .
    MAT2A-IN-2
  • HY-142928
    MAT2A-IN-1

    		Somatostatin Receptor Cancer
    MAT2A-IN-1 is a potent inhibitor of MAT2A. The expression level of MAT2A is abnormally high in several types of tumors, including gastric, colon, liver and pancreatic cancers. MAT2A-IN-1 reduces the proliferative activity of MTAP-deficient cancer cells. MAT2A-IN-1 has the potential for the research of cancer diseases (extracted from patent WO2021139775A1, compound 64) .
    MAT2A-IN-1
  • HY-158159
    IL17A-IN-1

    		Interleukin Related Inflammation/Immunology Cancer
    IL17A-IN-1 (compound 72) is an orally active Interleukin 17A inhibitor. IL17A-IN-1 can be used in the study of inflammatory and autoimmune diseases (plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis, etc.), as well as cancer .
    IL17A-IN-1
  • HY-115981
    NS5A-IN-2

    		HCV Protease Infection
    NS5A-IN-2 (Compound 33) is a potent inhibitor of NS5A. NS5A-IN-2 has extremely high potency against HCV genotype 1b, improved activity against genotype 3a (GT 3a) and good metabolic stability . NS5A-IN-2 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    NS5A-IN-2
  • HY-155755
    hCES2A-IN-1

    		Others Cancer
    hCES2A-IN-1 (compound 20w) is a potent hCES2A inhibitor, with an IC50 value of 1.6 nM. hCES2A-IN-1, a bysspectin A derivative, shows an approximately 1000-fold improvement over the lead compound bysspectin A .
    hCES2A-IN-1
  • HY-155228
    LK-44

    		Others Inflammation/Immunology
    hCES2A-IN-2 (Compound 44) is an orally active human carboxylesterase 2 (hCES2A) inhibitor (IC50: 5.02 μM). hCES2A-IN-2 improves Irinotecan (HY-16562)-induced delayed diarrhea .
    LK-44
  • HY-161298
    MAT2A-IN-15

    		Methionine Adenosyltransferase (MAT) Cancer
    MAT2A-IN-15 (compound 8) is an inhibitor of MAT2A .
    MAT2A-IN-15
  • HY-144433
    DNMT3A-IN-1

    		DNA Methyltransferase Infection
    DNMT3A-IN-1 is a potent and selective DNMT3A inhibitor. DNMT3A-IN-1 shows inhibitor activities against DNMT3A with kI values range from 9.16-18.85 μM (AdoMet) and 11.37-23.34 μM (poly dI-dC) .
    DNMT3A-IN-1
  • HY-145375
    NS5A-IN-1

    		HCV Protease Infection
    NS5A-IN-1 is a proagent of the HCV NS5A inhibitor Pibrentasvir (ABT-530).
    NS5A-IN-1
  • HY-142660
    PDE2A-IN-1

    		Phosphodiesterase (PDE) Neurological Disease
    PDE2A-IN-1 is a phosphodiesterase 2A (PDE2A) inhibitor with an IC50 value of 1.3 nM.
    PDE2A-IN-1
  • HY-162135
    MAT2A-IN-14

    		Methionine Adenosyltransferase (MAT) Reactive Oxygen Species Cancer
    MAT2A-IN-14 (compound H3) is a MAT2A inhibitor, and generates reactive oxygen species after sonication to specifically degrade cellular MAT2A via rapid oxidative reactions. Combination of MAT2A-IN-14 and sonication induces 87% MAT2A depletion in human colon cancer cell .
    MAT2A-IN-14
  • HY-157995
    Dyrk1A-IN-7

    		DYRK Metabolic Disease Inflammation/Immunology Cancer
    Dyrk1a-in-7 (Compound 29) is a selective DYRK1A kinase inhibitor, and has good kinase selectivity for CLK1 kinase. The IC50 value of DYRK1A is 28 nM. For CLK2, Kd is 17.5 nM. Dyrk1a-in-7 can be used in the research of cancer, type Ⅱ diabetes and neurological diseases .
    Dyrk1A-IN-7
  • HY-155595
    SNM1A-IN-1

    		Others Others
    SNM1A-IN-1 (compound 11a) is an inhibtor of SNM1A (a DNA damage repair enzyme with cytotoxicity) .
    SNM1A-IN-1
  • HY-139830
    Dyrk1A-IN-1

    		DYRK Neurological Disease
    Dyrk1A-IN-1 is a triple inhibitor of Dyrk1A kinase activity (IC50 = 119 nM) and the aggregation of tau and α-syn oligomers.
    Dyrk1A-IN-1
  • HY-147060
    Dyrk1A-IN-3

    		DYRK Neurological Disease
    Dyrk1A-IN-3 (Compound 8b), a highly selective  dual-specificity tyrosine-regulated kinase 1A (DYRK1A) inhibitor, maintains high levels of DYRK1A binding affinity (IC50=76 nM). Dyrk1A-IN-3 can be used for the research of neurodegenerative disorders such as Alzheimer’s Disease, Huntington’s Disease, and Parkinson’s Disease .
    Dyrk1A-IN-3
  • HY-44062
    G9a-IN-1

    		Histone Methyltransferase Inflammation/Immunology Cancer
    G9a-IN-1 (Compound 113) is a G9a protein inhibitor. G9A/EHMT2 is a nuclear histone lysine methyltransferase that catalyzes histone H3 lysine 9 dimethylation (H3K9me2), which is a reversible modification generally associated with transcriptional gene silencing. G9a-IN-1 can be used for the research of autoimmune disorders or cancer .
    G9a-IN-1
  • HY-153066
    KIF18A-IN-7

    		Microtubule/Tubulin Cancer
    KIF18A-IN-7 (Compound 22) is an orally active KIF18A inhibitor with an IC50 of 9.4 nM against KIF18A microtubule-dependent ATPase activity .
    KIF18A-IN-7
  • HY-153065
    KIF18A-IN-6

    		Microtubule/Tubulin Cancer
    KIF18A-IN-6 (Compound 134) is an orally active KIF18A inhibitor with an IC50 of 0.016 μM against KIF18A microtubule-dependent ATPase activity .
    KIF18A-IN-6
  • HY-100014
    KDM5A-IN-1
    2 Publications Verification

    		 Histone Demethylase Cancer
    KDM5A-IN-1 is a potent, orally bioavailable pan-histone lysine demethylases 5 (KDM5) inhibitor with IC50s of 45 nM, 56 nM and 55 nM for KDM5A, KDM5B and KDM5C, respectively, and with an EC50 value of 960 nM for PC9 H3K4Me3. KDM5A-IN-1 is significantly less potent against other KDM5B enzymes (1A, 2B, 3B, 4C, 6A, 7B) .
    KDM5A-IN-1
  • HY-146126
    NS5A-IN-4

    		HCV Protease Infection
    NS5A-IN-4 (Compound 1.12) is an orally active pan-genotypic hepatitis C virus (HCV) NS5A inhibitor with IC50 values of 1.2, 2296, 4.6, 362, 10.3 and 693 pM against gT1b, gT1a, gT2a, gT3a, gT4a and gT5a . NS5A-IN-4 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    NS5A-IN-4
  • HY-158164
    DNMT3A-IN-2

    		DNA Methyltransferase Cancer
    DNMT3A-IN-2 (compound 1a) is a hydrophthalazinone-based inhibitor of DNA methyltransferase 3A (DNMT3A) (IC50: 14 μM) against S-adenosylmethionine (SAM) has a Ki of 9.16-18.85 μM. .
    DNMT3A-IN-2
  • HY-108706
    KDM2A/7A-IN-1

    		Histone Demethylase Cancer
    KDM2A/7A-IN-1 is a first-in-class, selective and cell-permeable inhibitor of histone lysine demethylases KDM2A/7A, with an IC50 of 0.16 μM for KDM2A, exhibits 75 fold selevtivity over other JmjC lysine demethylases, and is inactive on methyl transferases, and histone acetyl transferases .
    KDM2A/7A-IN-1
  • HY-W099547
    Dihexadecyl hydrogen phosphate

    		Liposome Others
    Dihexadecyl hydrogen phosphateIt is an organic compound belonging to phospholipids. It's often used as an emulsifier, which means it helps mix two substances together that don't usually mix well, such as oil and water. Dihexadecyl hydrogen phosphateIt has several applications in the food industry, especially in the production of processed foods where it improves texture and stability. Additionally, it has applications in the pharmaceutical industry where it can be used ain the generation of micelles, liposomes, and other types of artificial membranes.
    Dihexadecyl hydrogen phosphate
  • HY-136535
    Anizatrectinib

    hTrkA-IN-1

    		 Trk Receptor Inflammation/Immunology
    Anizatrectinib (hTrkA-IN-1) is a potent and orally active inhibitor of TrkA kinase with an IC50 of 1.3 nM, compound 2 extracted from patent WO2015175788. Anizatrectinib can be used for the study of inflammatory disease, such as prostatitis, pelvic, et al .
    Anizatrectinib

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: